{"id":"dc-cik","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DC-CIK combines dendritic cells (antigen-presenting cells) with cytokine-induced killer cells to create a personalized cellular immunotherapy. The dendritic cells are loaded with tumor antigens to prime immune recognition, while the CIK cells provide cytotoxic effector function. This combination aims to enhance anti-tumor immunity by bridging innate and adaptive immune responses.","oneSentence":"DC-CIK is a dendritic cell-cytokine induced killer cell immunotherapy that activates and expands autologous immune cells to target and destroy cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:43.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Gastric cancer"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07343791","phase":"EARLY_PHASE1","title":"Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.","status":"RECRUITING","sponsor":"JIANG LONGWEI","startDate":"2025-11-19","conditions":"DC-CIK Treatment, Regorafenib, Colorectal Cancer","enrollment":14},{"nctId":"NCT07260058","phase":"PHASE1, PHASE2","title":"Immune Cell Therapy for Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","startDate":"2025-12-01","conditions":"Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally Advanced or Metastatic)","enrollment":48},{"nctId":"NCT07204496","phase":"","title":"A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2025-09-26","conditions":"Advanced Bladder Cancer","enrollment":20},{"nctId":"NCT01898663","phase":"PHASE1, PHASE2","title":"DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML","status":"RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2013-06","conditions":"High-risk Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT03393858","phase":"PHASE1, PHASE2","title":"Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma","status":"TERMINATED","sponsor":"Capital Medical University","startDate":"2017-12-01","conditions":"Cancer, Mesothelioma, Malignant","enrollment":10},{"nctId":"NCT01906632","phase":"NA","title":"Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-05","conditions":"Malignant Tumor","enrollment":50},{"nctId":"NCT01691625","phase":"NA","title":"Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Carcinoma","enrollment":50},{"nctId":"NCT01884168","phase":"","title":"Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-03","conditions":"Malignant Tumor","enrollment":30},{"nctId":"NCT03190811","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-09","conditions":"Neoplasms","enrollment":100},{"nctId":"NCT03360630","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2016-11-01","conditions":"Lung Cancer, Neoplasms","enrollment":60},{"nctId":"NCT05955157","phase":"PHASE2, PHASE3","title":"Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2023-01-03","conditions":"Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor","enrollment":52},{"nctId":"NCT04214717","phase":"NA","title":"Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Yantai Yuhuangding Hospital","startDate":"2019-12-31","conditions":"Solid Tumor","enrollment":60},{"nctId":"NCT05622825","phase":"PHASE1, PHASE2","title":"Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2023-01","conditions":"Advanced Liver Cancers","enrollment":15},{"nctId":"NCT05020119","phase":"PHASE1","title":"Neoantigen-expanded Autologous Immune Cell Therapy","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-04-09","conditions":"Advanced Solid Tumor","enrollment":9},{"nctId":"NCT02851784","phase":"PHASE2, PHASE3","title":"Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2009-12","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT04476641","phase":"PHASE2","title":"A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-05-06","conditions":"Liver Cancer, Kidney Cancer, Nasopharyngeal Cancer","enrollment":686},{"nctId":"NCT04292769","phase":"PHASE3","title":"Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors","status":"UNKNOWN","sponsor":"Li Yu","startDate":"2020-01-21","conditions":"Malignant Neoplasm","enrollment":200},{"nctId":"NCT01691664","phase":"NA","title":"Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2012-09","conditions":"Esophageal Cancer","enrollment":40},{"nctId":"NCT02425748","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2017-06-08","conditions":"Lung Cancer","enrollment":40},{"nctId":"NCT03815630","phase":"EARLY_PHASE1","title":"A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors","status":"UNKNOWN","sponsor":"Allife Medical Science and Technology Co., Ltd.","startDate":"2019-02-01","conditions":"Solid Tumor","enrollment":100},{"nctId":"NCT01783951","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-02-01","conditions":"Gastric Cancer","enrollment":63},{"nctId":"NCT01781520","phase":"PHASE1, PHASE2","title":"Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2013-06-01","conditions":"Pancreatic Cancer","enrollment":47},{"nctId":"NCT03158480","phase":"NA","title":"Safety and Efficacy of Immune Therapy for Condyloma","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2017-06-25","conditions":"Condylomata Acuminata","enrollment":80},{"nctId":"NCT03057340","phase":"PHASE1","title":"The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2017-06-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT03047525","phase":"PHASE1, PHASE2","title":"Study of DC-CTL Combined With CIK for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Xiaoyi Huang","startDate":"2017-02-20","conditions":"Colorectal Cancer, Renal Cell Carcinoma, Nasopharyngeal Carcinoma","enrollment":200},{"nctId":"NCT02539017","phase":"PHASE2","title":"The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer","status":"WITHDRAWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2015-11","conditions":"Triple Negative Breast Neoplasms","enrollment":""},{"nctId":"NCT02418481","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-04","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT02425735","phase":"PHASE1, PHASE2","title":"Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2015-04","conditions":"Liver Cancer","enrollment":40},{"nctId":"NCT02487017","phase":"PHASE2","title":"DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2015-05","conditions":"Hepatocellular Carcinoma, Neoplasms, Digestive System Neoplasms","enrollment":60},{"nctId":"NCT02644863","phase":"PHASE2","title":"Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2015-12","conditions":"Esophageal Neoplasms, Neoplasms, Digestive System Neoplasms","enrollment":60},{"nctId":"NCT02693236","phase":"PHASE1, PHASE2","title":"DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-08","conditions":"Esophagus Cancer","enrollment":30},{"nctId":"NCT02412384","phase":"","title":"The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2013-06","conditions":"Neoplastic Cells, Circulating","enrollment":120},{"nctId":"NCT02491697","phase":"PHASE2","title":"Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2016-02","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT02688673","phase":"PHASE1, PHASE2","title":"DC Vaccine Combined With CIK Cells in Patients With SCLC","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-08","conditions":"Small- Cell Lung Cancer","enrollment":30},{"nctId":"NCT02688686","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2016-02","conditions":"Non-Small-Cell Lung Cancer With Bone Metastases","enrollment":30},{"nctId":"NCT01924156","phase":"PHASE1, PHASE2","title":"DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2013-07","conditions":"Renal Cell Carcinoma","enrollment":30},{"nctId":"NCT01956630","phase":"PHASE1, PHASE2","title":"Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2013-09","conditions":"Acute Leukemia","enrollment":25},{"nctId":"NCT02406846","phase":"","title":"The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2013-06","conditions":"Neoplastic Cells, Circulating","enrollment":80},{"nctId":"NCT02450435","phase":"","title":"The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2013-06","conditions":"Neoplastic Cells, Circulating","enrollment":60},{"nctId":"NCT02450448","phase":"","title":"The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2013-06","conditions":"Neoplastic Cells, Circulating","enrollment":60},{"nctId":"NCT02450357","phase":"","title":"The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2013-06","conditions":"Neoplastic Cells, Circulating","enrollment":60},{"nctId":"NCT02416635","phase":"","title":"The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2013-06","conditions":"Neoplastic Cells, Circulating","enrollment":60},{"nctId":"NCT02450422","phase":"","title":"The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment","status":"COMPLETED","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2013-06","conditions":"Neoplastic Cells, Circulating","enrollment":60},{"nctId":"NCT02202928","phase":"PHASE2","title":"Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2014-07","conditions":"Colorectal Cancer, Neoplasms, Intestinal Neoplasms","enrollment":60},{"nctId":"NCT01232062","phase":"","title":"Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2010-08","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":46},{"nctId":"NCT01395056","phase":"","title":"Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2011-07","conditions":"Breast Neoplasms, Neoplasm Metastasis","enrollment":23},{"nctId":"NCT02504229","phase":"PHASE2","title":"DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment","status":"UNKNOWN","sponsor":"Beijing Biohealthcare Biotechnology Co.,Ltd","startDate":"2014-11","conditions":"Gastric Cancer","enrollment":80},{"nctId":"NCT02487550","phase":"PHASE2","title":"DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating","status":"NOT_YET_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2015-08","conditions":"Renal Neoplasma","enrollment":1200},{"nctId":"NCT02415699","phase":"PHASE2, PHASE3","title":"DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2015-08","conditions":"Colorectal Cancer","enrollment":100},{"nctId":"NCT01839539","phase":"PHASE2","title":"Study of DC-CIK to Treat Colorectal Cancer","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2013-03","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT01821482","phase":"PHASE2","title":"A Study of DC-CIK to Treat Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2013-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":100},{"nctId":"NCT01821495","phase":"PHASE2","title":"Study of DC-CIK to Treat NPC","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2013-05","conditions":"Nasopharyngeal Carcinoma","enrollment":100},{"nctId":"NCT00862303","phase":"PHASE1, PHASE2","title":"DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Fuzhou General Hospital","startDate":"2009-03","conditions":"Renal Cell Carcinoma","enrollment":100},{"nctId":"NCT01235845","phase":"PHASE1, PHASE2","title":"Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma","status":"UNKNOWN","sponsor":"Qingdao University","startDate":"2011-01","conditions":"Malignant Glioma","enrollment":30},{"nctId":"NCT01240005","phase":"PHASE1, PHASE2","title":"Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Qingdao University","startDate":"2011-01","conditions":"Renal Cell Carcinoma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":178,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["1"],"phase":"phase_3","status":"active","brandName":"DC-CIK","genericName":"DC-CIK","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"DC-CIK is a dendritic cell-cytokine induced killer cell immunotherapy that activates and expands autologous immune cells to target and destroy cancer cells. Used for Hepatocellular carcinoma, Gastric cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}